Can-Fite BioPharma (CANF) Announces Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million
Get Alerts CANF Hot Sheet
Join SI Premium – FREE
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the six existing distribution agreements it has signed for its advanced stage drug candidates Piclidenoson and Namodenoson in select territories have remaining potential milestone payments of up to approximately $130 million plus double digit royalties on net sales following regulatory approval. In addition, to date, the Company has collected over $20 million in non-dilutive upfront and milestone payments.
Distribution agreements have been signed covering Canada, Spain, Switzerland, Austria, Central Eastern Europe, China, Hong Kong, Macao, and South Korea. Can-Fite is actively in talks with prospective distribution partners in other major markets and intends to optimize the value of potential future agreement based on advancements in its clinical pipeline. The world’s largest pharma market, the U.S., as well as other major markets including Japan, Germany, France, Italy, the UK, and others remain untapped opportunities for Can-Fite.
“Can-Fite’s robust clinical proof of concept and its effective business development strategy, combined with our core strength in small molecule drug innovation, enables us to forge partnerships with a growing number of global distribution partners. While our current distribution agreements have a potential for up to approximately $130 million in milestone payments, we continue to pursue opportunities in the largest pharmaceutical markets which we believe have the potential for substantial additional value,” stated Can-Fite CEO Dr. Pnina Fishman.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
- Methanex (MEOH) Appoints Roger Perreault to its Board
- Workday (WDAY) Announces Resignation of Ann-Marie Campbell from Board
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!